FluoroPharma Medical, Inc.

Equities

FPMI

US3438701019

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 11:35:55 2024-02-26 am EST			5-day change	1st Jan Change
0.0001 ^USD	-50.00%		-.--%	-.--%

2022	FluoroPharma Medical, Inc. Announces Executive Changes	CI
2022	FluoroPharma Medical, Inc. Appoints Frank I Igwealor as CFO	CI

Fluoropharma Medical, Inc. Presents Data from Phase II Clinical Trial of 18F FCPHA

May 29, 2014 at 08:33 am EDT

FluoroPharma Medical, Inc. announced that data and analysis from a feasibility study on the quantification of myocardial perfusion in humans by PET/CT utilizing the fatty acid analogue (18) F-FCPHA at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting.

Latest news about FluoroPharma Medical, Inc.

FluoroPharma Medical, Inc. Announces Executive Changes	22-06-23	CI
FluoroPharma Medical, Inc. Appoints Frank I Igwealor as CFO	22-06-23	CI
FluoroPharma Medical, Inc. Restructures CardioPET License With Massachusetts General Hospital	18-09-27	CI
FluoroPharma Medical, Inc. cancelled the acquisition of Ground Fluor Pharmaceuticals, Inc.	17-06-08	CI
FluoroPharma Medical, Inc. Auditor Raises 'Going Concern' Doubt	17-03-30	CI
FluoroPharma Medical, Inc. Announces Resignation of Lawrence Atinsky as Director and Member of Audit Committee and Compensation Committee of the Board of Directors	17-03-02	CI
FluoroPharma Medical, Inc. Borrows $50,000 in the Form of Promissory Note; Announces Board Resignations, Effective January 1, 2017	16-12-29	CI
FluoroPharma Medical, Inc. announced that it has received $0.57 million in funding	16-11-28	CI
FluoroPharma Medical Inc. and Royal Philips Collaborate on Image Management for CardioPET Phase II Clinical Trial	16-10-18	CI
FluoroPharma Medical, Inc. (OTCPK: FPMI) entered into a nonbinding letter of intent to acquire Ground Fluor Pharmaceuticals, Inc.	16-06-08	CI
FluoroPharma Medical, Inc. Enters into Development and Commercialization Agreement with Sinotau USA Inc. for China and Canada	16-06-06	CI
Fluoropharma Medical Inc. Accepts First Comparative Data from it's Phase II Trial of CardioPET in Subjects with High Likelihood of Coronary Artery Disease	16-05-25	CI
FluoroPharma Medical, Inc. Auditor Raises 'Going Concern' Doubt	16-03-29	CI
FluoroPharma Medical, Inc. announced that it expects to receive $1 million in funding	16-03-22	CI
FluoroPharma Medical, Inc. Announces Resignation of Andrew H. Sassine as Member of the Board of Directors	16-01-14	CI
FluoroPharma Medical, Inc. Announces Management Appointments	15-12-29	CI
FluoroPharma Medical, Inc. Announces Board Changes	15-11-12	CI
FluoroPharma Medical Inc Appoints Dr. Thomas H. Tulip as President	15-10-06	CI
FluoroPharma Medical, Inc. announced that it has received $2.78 million in funding	15-09-28	CI
FluoroPharma Medical, Inc. announced that it has received $0.195 million in funding.	15-07-01	CI
FluoroPharma Medical, Inc. announced that it expects to receive $2 million in funding.	15-05-27	CI
FluoroPharma Medical, Inc. Auditor Raises 'Going Concern' Doubt	15-03-30	CI
FluoroPharma Medical, Inc. announced that it has received $2 million in funding.	14-12-28	CI
FluoroPharma Medical, Inc. Announces the Data from its Phase II Clinical Trial of 18-F FCPHA	14-09-22	CI
FluoroPharma Medical, Inc. announced that it expects to receive $1.98 million in funding.	14-07-21	CI

Chart FluoroPharma Medical, Inc.

Duration

Period

More charts

Company Profile

FluoroPharma Medical, Inc. is a biopharmaceutical company specializing in discovering, developing and commercializing molecular imaging pharmaceuticals with initial applications in the area of cardiology. The Company is focused on the development of cardiovascular imaging agents that detect and assess acute and chronic forms of coronary artery disease (CAD). It has two clinical-stage molecular imaging pharmaceutical product candidates: 18-F TPP (BFPET) and 18-F FCPHA (CardioPET). BFPET program employs a (18F)-labeled cationic lipophilic tetraphenylphosphonium ion as an imaging agent designed for use in stress-testing for patients with presumptive or proven CAD. It measures the extent and severity of cardiovascular disease through the detection of ischemic and infarcted myocardial tissue. CardioPET program employs Trans-9-(18F)-Fluoro-3, 4-Methyleneheptadecanoic Acid as a molecular imaging agent designed to assess myocardial blood flow and metabolism in patients with CAD.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
FLUOROPHARMA MEDICAL, INC.	-.--%	2.76K
MODERNA, INC.	+22.56%	46.71B
IQVIA HOLDINGS INC.	-1.51%	41.52B
LONZA GROUP AG	+48.83%	41.8B
CELLTRION, INC.	-3.42%	29.55B
ICON PUBLIC LIMITED COMPANY	+10.13%	25.78B
ALNYLAM PHARMACEUTICALS, INC.	-20.44%	19.26B
MEDPACE HOLDINGS, INC.	+26.45%	11.98B
BIO-TECHNE CORPORATION	-0.14%	12.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.47%	12.08B

Other Biotechnology & Medical Research